Clinical trial
Phase I Study of T Cells Expressing an Anti-CD22 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
NCT04163575 is registered in ClinicalTrials.gov with Kecellitics Biotech Company Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of T Cells Expressing an Anti-CD22 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
- Lead sponsor
- Kecellitics Biotech Company Ltd
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- February 1, 2020
- Completion date
- July 1, 2022
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.